Related Experiment Video

Updated: Aug 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Intensive lipid-lowering therapy in patients with coronary heart disease

Stacy A Lauderdale1, Amy Heck Sheehan

  • 1McWhorter School of Pharmacy, Samford University, Drug Information Specialist, Samford University Global Drug Information Service, Birmingham, AL 35229-7027, USA. salauder@samford.edu

The Annals of Pharmacotherapy
|December 23, 2004
PubMed

Insights

Intensive lipid-lowering therapy significantly lowers LDL-C and may reduce cardiovascular events in acute coronary syndrome (ACS) patients. More research is needed for stable coronary heart disease.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Coronary heart disease (CHD) management often involves lipid-lowering therapy.
  • The optimal intensity of lipid-lowering therapy for CHD patients remains an area of investigation.

Purpose of the Study:

  • To review current evidence on intensive lipid-lowering therapy (LLT) in patients with coronary heart disease.
  • To compare the clinical outcomes of intensive versus conventional LLT.

Main Methods:

  • A comprehensive literature search was performed using MEDLINE (1966-2004).
  • Keywords included "lipoproteins," "low-density lipoprotein cholesterol (LDL-C)," "HMG-CoA reductase inhibitors," "coronary arteriosclerosis," and "coronary disease."
  • Included studies compared intensive and conventional LLT regimens.

Main Results:

  • Intensive LLT achieved significantly greater reductions in LDL-C compared to conventional treatment.
  • Evidence suggests intensive LLT may reduce cardiovascular morbidity and mortality in patients with recent acute coronary syndrome (ACS).
  • Clinical benefits of intensive LLT in stable coronary heart disease are not yet established.

Conclusions:

  • Patients with ACS may benefit from intensive lipid-lowering therapy, although data are limited.
  • Ongoing studies aim to define the precise role of intensive LLT in CHD management.
Abstract

More Related Videos

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...